




# Correction

## Correction: Myelopoietic Efficacy of Orlistat in Murine Hosts Bearing T Cell Lymphoma: Implication in Macrophage Differentiation and Activation

The PLOS ONE Staff

Figure 1, Figure 6, and Equation 1 have been corrected for better readability.

Figure 1 is incorrect. The authors have provided a corrected version here.




**Figure 1. Protocol for administering orlistat to tumor-bearing mice.** Mice were transplanted DL cells (1x10<sup>5</sup> cells/0.5 ml PBS) on day 0 following administration of Vehicle alone (control) or containing orlistat 240mg/kg body weight/day up to day 14 post tumor transplantation. On day 16 BMC were harvested from femurs.  
doi:10.1371/journal.pone.0082396.g001

**Citation:** The PLOS ONE Staff (2014) Correction: Myelopoietic Efficacy of Orlistat in Murine Hosts Bearing T Cell Lymphoma: Implication in Macrophage Differentiation and Activation. PLoS ONE 9(3): e93312. doi:10.1371/journal.pone.0093312

**Published:** March 24, 2014

**Copyright:** © 2014 The PLOS ONE Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Figure 6 is incorrect. The authors have provided a corrected version here.



**Figure 6. BMDM obtained from BMC of orlistat-administered groups display M1 Mφ phenotype.** BMDM differentiated from BMC of control or orlistat-administered tumor-bearing mice were incubated *in vitro* for 24h in medium alone or containing IFN-γ (100IU/ml) + LPS (10ng/ml) followed by estimation of NO (a), indicated cytokines by ELISA in culture supernatant (b), assay of ROS expression (d,e), phagocytosis (c), BMDM-mediated tumoricidal activity (f,g) and expression of cell surface functional markers: CD11c and TLR2 (h). Values shown in (a,b,e,f,g) mean ± SD of three independent experiments done in triplicate. \**p*<0.05 vs. values of respective control. \*\**p*<0.05 vs. values for orlistat and LPS + IFN-γ treated control groups. Arrows indicates increased phagocytosis (c), expression of ROS (d) and CD11c & TLR-2 (h) in BMDM of orlistat group treated with IFN-γ + LPS.

doi:10.1371/journal.pone.0082396.g002

Equation 1 is incorrect. The authors have provided a corrected version here.

$$\% \text{ cytotoxicity} = \frac{(O.D. \text{ of } DL \text{ cells incubated alone} + O.D. \text{ of } BMDM \text{ incubated alone}) - O.D. \text{ of } DL \text{ cells incubated with } BMDM}{O.D. \text{ of } DL \text{ cells incubated alone} + O.D. \text{ of } BMDM \text{ incubated alone}} \times 100$$

## Reference

1. Kant S, Kumar A, Singh SM (2013) Myelopoietic Efficacy of Orlistat in Murine Hosts Bearing T Cell Lymphoma: Implication in Macrophage Differentiation and Activation. PLoS ONE 8(12): e82396. doi:10.1371/journal.pone.0082396